S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Second Sight’s Argus® II Retinal Prosthetic Implant to be Sold in Turkey (2014/12/17)|
|Health Canada Approves Second Sight’s Argus II Retinal Prosthesis System for Treatment of Outer Retinal Degeneration (2015/1/12)|
|Second Sight Announces First Commercial Implants of the Argus® II Retinal Prosthesis System in France (2015/2/24)|
|Second Sight Receives Highest Priority Reimbursement for Argus II in Germany (2015/2/3)|
|Second Sight to Present at the 27th Annual ROTH Conference on March 9, 2015 (2015/2/23)|
|Second Sight to Discuss Fourth Quarter and Year-End 2014 Financial Results on March 11, 2015 Conference Call (2015/2/27)|
|Imprimis Pharmaceuticals and Cleveland Eye Clinic Announce Positive Findings of Evaluation of LessDrops™ Combination Eye Drop Formulations Following LASIK Surgery (2015/2/3)|
|Imprimis Pharmaceuticals to Highlight its Proprietary Ophthalmic Solutions at the Hawaiian Eye 2015 and the Cataract Surgery: Telling It Like It Is! Meetings (2015/1/13)|
|Imprimis Pharmaceuticals Looks to Expand its Ophthalmology Portfolio with LessDrops™ (2015/1/8)|
|Ocular Therapeutix™ Enrolls First Patient in Phase 2 Clinical Trial for Sustained Release Dexamethasone for the Treatment of Dry Eye Disease (2015/1/21)|
Click above to view more mutual fund data and stats for eyes - Second Sight Medical Products Inc.